Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer

Share this content:
Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer
Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer

SAN ANTONIO – Extended treatment with letrozole for 5 years did not significantly improve disease-free survival in women with hormone receptor (HR)-positive breast cancer receiving adjuvant endocrine therapy after 5 years of tamoxifen, a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) has shown.1

“Extended adjuvant endocrine therapy after 5 years of tamoxifen with either an aromatase inhibitor or tamoxifen improves disease-free survival in early-stage breast cancer, but the optimal duration of adjuvant aromatase inhibitor therapy beyond 5 years is unknown,” said Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health. “NSABP B-42 aimed to determine whether 5 years of letrozole vs placebo improves disease-free survival in patients who have completed 5 years of hormonal therapy with either an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor.

For the double-blind, phase 3 NRG Oncology/NSABP B-42 (ClinicalTrials.gov Identifier: NCT00382070), investigators enrolled 3966 postmenopausal women with stage I to III, estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, invasive breast cancer who were free of disease after 5 years of either an aromatase inhibitor or tamoxifen for no more than 3 years, followed by an aromatase inhibitor for the remainder of the 5-year period. Of those, 34% were younger than 60 years, 57% were node-negative, 39% received prior tamoxifen, 61% had undergone breast-conserving surgery, and 14% had HER2-positive disease.

Participants were randomly assigned to receive letrozole 2.5 mg orally daily or placebo for an additional 5 years.

After a median follow-up of 6.9 years, results showed that extended tamoxifen therapy was associated with an improvement in disease-free survival compared with placebo (hazard ratio [HR], 0.85; 95% CI, 0.73-0.999; P =.048). The P-value did not reach the statistical significance level of .0418. Results were consistent when adjusting for age or type of surgery received.

The 7-year disease-free survival was 84.7% with letrozole and 81.3% with placebo. After adjusting for multiple variables, analyses showed that treatment, age, pathologic nodal status, prior tamoxifen status, and surgery type were significantly associated with disease-free survival.

Researchers also found no significant difference in overall survival between the 2 treatment arms (HR, 1.15; 95% CI, 0.92-1.44; P =.22). Seven-year overall survival was 91.8% with letrozole vs 92.3% with placebo.

“The beneficial effect of extended letrozole therapy on disease-free survival did not reach statistical significance,” said Dr Mamounas. “There was also no significant difference in overall survival with letrozole vs placebo.”

However, the study demonstrated a statistically significant reduction of 29% in breast cancer-free interval (BCFI) events and a statistically significant 28% decrease in distant recurrence (DR) with extended letrozole therapy compared with placebo (HR for BCFI, 0.71; 95% CI, 0.56-0.90; P =.003 and HR for DR, 0.72; 95% CI, 0.53-0.97; P =.03).

There was no significant difference in osteoporotic fractures (P =.27) or arterial thrombotic events (P =.33) between the 2 groups, but Dr Mamounas noted that the risk of arterial thrombotic events was elevated for the letrozole arm after 2 years.

Of note, treatment compliance was similar between the 2 arms. Overall, 62.5% of patients who were given placebo and 60.3% of letrozole-treated patients completed 5 years of therapy. Nearly 10% discontinued letrozole therapy due to an adverse event.

“Our findings suggest that careful assessment of potential risks and benefits is required before recommending extended letrozole therapy to patients with early-stage breast cancer, including: patient and tumor characteristics; existing comorbidities; information on bone mineral density; and tolerance of the aromatase inhibitor in the initial 5 years,” Dr Mamounas said.

Dr Mamounas concluded: “Genomic classifiers that predict risk of late recurrence and/or benefit from extended endocrine therapy may help to further individualize the recommendation for extended aromatase inhibitor therapy.”


1. Mamounas EP, Bandos H, Lembersky BC, et al. A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Paper presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs